Ablynx NV
Ablynx NV [ABLX] is focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases including inflammation, haematology, oncology and pulmonary disease.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Exit
Website
www.ablynx.com
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.